Trends in the Use of Mifepristone for Medical Management of Early Pregnancy Loss From 2016 to 2020

JAMA. 2023 Aug 22;330(8):766-3. doi: 10.1001/jama.2023.13628.

Authors

Elise W Boos¹, Manuel Horta², Ivana Thompson³, Stacie B Dusetzina², Ashley A Leech²

Affiliations

¹ Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee.
² Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
³ Department of Obstetrics and Gynecology, University of Washington, Seattle.

No abstract available

Plain language summary

This study assesses the use of mifepristone plus misoprostol for miscarriage management among commercially insured adults in the US.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Abortifacient Agents, Nonsteroidal* / therapeutic use
Abortion, Spontaneous* / drug therapy
Female
Humans
Mifepristone* / therapeutic use
Misoprostol
Pregnancy

Substances

Abortifacient Agents, Nonsteroidal
Mifepristone
Misoprostol

Grants and funding

K01 DA050740/DA/NIDA NIH HHS/United States